Canny_Mannie
01 Apr 2019
Sell Off ITDYA Well, back up to 61.69 as I type so still not conclusive as to why AZN dropped so much. Still, my original buy price was 29.47 (OK in 2011) so I can’t complain too much! CM
In_the_dark_yet_again
31 Mar 2019
Sell Off LSE:AZN @Canny_Mannie [link] It was 3.5bn USD (£2.7bn), placement, already done at £60.50. But I read somewhere a fair chunk went to Daiichi Sankyo as part of the overall deal and the rest to existing major shareholders, clearly a sweetener to get it done. Ordinary individual private shareholder get shafted as usual (albeit only slightly) Don’t think it can just be the placement because more money was wiped of the market cap than they actually raise. I can only think there’s something in the details of the deal that the City really doesn’t like unless it’s a bit of underhand price manipulation - from a base of just under £65 they wouldn’t be allowed to place shares at £60.50, the discount is too great. From a £61.50 base, no issue, their existing mandate allows them. If it bounces straight back to anywhere near £65 then it’s price manipulation (i.e. criminal, fraud) IMO albeit probably impossible to prove. If it stays down here or falls then there’s something ugly in the detail… or something else going on, hence my original question. Regards, ITDYA thinking this kind of placement, if there has been an artificial SP markdown is, if not actually illegal, at least immoral… but then again it wouldn’t be the 1st time the big boys have taken care of each other at everyone else’s expense.
Canny_Mannie
29 Mar 2019
Sell Off I suppose hitting the market for a 3.5bn fundraising does not go down so well with investors if it turns out to be a Rights Issue and dilutes existing investors. Time will tell. GLTA CM
In_the_dark_yet_again
29 Mar 2019
Sell Off LSE:AZN Daiichi Sankyo: [link] Is this deal that bad to cause a 5% sell-off or is there something else that I’ve missed? Regards, ITDYA
Vee_Jay_R
27 Oct 2018
A bit quiet on this board Is there another site where you can run a virtual portfolio. Since iii changed to this it is rubbish
frog_in_a_tree
16 Oct 2018
Investment freeze From the Daily Telegraph: "Pharmaceutical giant AstraZeneca has suspended investments in Britain due to the lack of clarity over the country’s departure from the European Union. With less than six months to go, Leif Johansson, non-executive chairman, told France’s Le Monde newspaper precautions had to be taken. “If a transition deal does not make clear what will happen in the future, we will maintain our decision not to invest,†Mr Johansson said. “A Brexit agreement will need to ensure that Britain does not become an isolated island in the middle of the Atlantic Ocean.†Frog in a tree
frog_in_a_tree
09 Sep 2018
A bit quiet on this board …for a major divi paying stock. Anyway, interim divi day this maorning. Good luck all! Frog in a tree
Proverbs 26 vs 5
02 Jun 2018
American Society of Clinical Oncology annual meeting American Society of Clinical Oncology annual meeting: The annual meeting of oncology professionals runs this weekend through June 5 in Chicago. Companies on watch for developments with various Phase 1 and Phase 2 data updates include Celgene (NASDAQ:CELG), bluebird bio (NASDAQ:BLUE), Nektar Therpeutics (NASDAQ:NKTR), Bristol-Myers Squibb (NYSE:BMY), Merck (NYSE:MRK), Tesaro (NASDAQ:TSRO), AstraZeneca Group (NYSE:AZN), AbbVie (NYSE:ABBV) and Jounce Therapeutics (NASDAQ:JNCE).
Proverbs 26 vs 5
29 May 2018
Well worth reading Lots of good stuff in this article.Follow the link:[link]
Proverbs 26 vs 5
25 May 2018
AstraZeneca successful in late-state lung cancer study A Phase 3 clinical trial, PACIFIC, assessing AstraZeneca's (NYSE:AZN) Imfinzi (durvalumab) in patients with unresectable Stage III non-small cell lung cancer (NSCLC) whose cancer has not progressed following platinum-chemo concurrent with radiation therapy met the second of two primary endpoints.An interim analysis by the independent Data Monitoring Committee showed that treatment with Imfinzi resulted in a statistically significant improvement in overall survival (OS) compared to placebo. The results will be submitted for presentation at an upcoming medical conference.In May 2017, the company announced that the study met the first primary endpoint, demonstrating a statistically valid improvement in median progression-free survival (PFS) compared to control.Imfinzi is approved in the U.S. and Canada for the indication. Marketing applications are currently under review in Europe, Japan and certain other countries.
FRTEB
24 May 2018
Re: Selling signal? " I've been holding for 4 years from around the time of the Pfizer bid. " Blimey, have four years really passed since the Pfizer bid? It seems like yesterday.
maaark1
23 May 2018
Re: Selling signal? I wouldn't call a top on this one, sales and profits have been falling for the past few years and the share price keeps going up.I've been in this one since the Astra days, 1st tranche at £8.50. Been a regular trader since then, I've noticed that the share price over reacts to studies which the city have heard of. If a trial goes well, the share prices shoots up and I sell, it usually drifts back. If there's a negative result (Mystic) the price tanks, I buy and it usually recovers.I have no idea what the share price should be, I keep expecting it to drop and it doesn't. If Pfizer offered £55 they will have priced in a big premium to encourage the funds to accept. This means they thought the correct price was considerably lower than £55, yet here we are at £54.40Sales and profits are due to go up either next year or the year after next. That's probably when the price will start falling seeing as it's gone up while profits are falling.Good luck whichever way you go.
Profitcruncher
23 May 2018
Selling signal? I've been holding for 4 years from around the time of the Pfizer bid. If I remember correctly, they bid £55 and were rejected. It's taken this long to get near that level. I will be out of it gets close to £55. Anyone thinks this will go higher?
Proverbs 26 vs 5
21 May 2018
New application in Japan AstraZeneca said Monday it had submitted a new drug application to Japan's Pharmaceuticals and Medical Devices Agency for its oral adjunct treatment to insulin in adults with type-1 diabetes. The application was based on Phase III data from the DEPICT - Dapagliflozin Evaluation in Patients with Inadequately Controlled Type 1 Diabetes - clinical programme for Forxiga in type-1 diabetes and a dedicated trial in Japanese patients. The application for Forxiga, which provided the added benefits of blood pressure reductions and weight loss in adult patients with type-2 diabetes, comes after regulatory submission for the drug was accepted in Europe earlier this year, the firm said Story provided by StockMarketWire.com
Proverbs 26 vs 5
21 May 2018
New FDA approval AstraZeneca announced Monday the US Food and Drug Administration had approved its hyperkalaemia drug, a serious condition associated with elevated levels in the blood. The US Food and Drug Administration's approval of Lokelma, an oral potassium-removing agent, was supported by data from three double-blind, placebo-controlled trials and two open-label trials showing the drug helped to normalise potassium levels. 'The consequences of hyperkalaemia can be very serious and it's reassuring for treating physicians that Lokelmahas demonstrated lowering of potassium levels in patients with chronic kidney disease, heart failure, diabetes and those taking RAAS inhibitors,' said Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca. 'This FDA approval represents an exciting milestone, as it stands to deliver a rapid, effective and generally well-tolerated treatment option to patients suffering from hyperkalaemia in the US,' said Steven Fishbane, MD, Professor, Donald and Barbara Zucker School of Medicine at Hofstra Northwell, New York. Story provided by StockMarketWire.com
